SK287357B6 - Použitie antagonistu alfa v beta 3 na prípravu farmaceutickej kompozície na liečbu tumorových buniek a terapeutická kompozícia a súprava na liečenie tumoru alebo tumorových metastáz - Google Patents

Použitie antagonistu alfa v beta 3 na prípravu farmaceutickej kompozície na liečbu tumorových buniek a terapeutická kompozícia a súprava na liečenie tumoru alebo tumorových metastáz Download PDF

Info

Publication number: SK287357B6
Authority: SK; Slovakia
Prior art keywords: tumor; antigen; antitumor; angiogenesis; kit
Prior art date: 1999-02-12

Application number

SK1113-2001A

Other languages

English (en)

Slovak (sk)

Other versions

SK11132001A3 (sk

Inventor

Holger N. Lode

Ralph A. Reisfeld

David A. Cheresh

Stephen D. Gillies

Original Assignee

The Scripps Research Institute

Lexigen Pharmaceuticals Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-12

Filing date

2000-02-11

Publication date

2010-08-09

2000-02-11 Application filed by The Scripps Research Institute, Lexigen Pharmaceuticals Corporation filed Critical The Scripps Research Institute

2002-06-04 Publication of SK11132001A3 publication Critical patent/SK11132001A3/sk

2010-08-09 Publication of SK287357B6 publication Critical patent/SK287357B6/sk

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 241
206010027476 Metastases Diseases 0.000 title claims abstract description 49
239000000203 mixture Substances 0.000 title claims abstract description 32
210000004881 tumor cell Anatomy 0.000 title claims abstract description 30
230000001225 therapeutic effect Effects 0.000 title claims abstract description 27
238000002360 preparation method Methods 0.000 title claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 4
HGFOOLONGOBCMP-IBGZPJMESA-N (3s)-3-(6-methoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=NC(OC)=CC=C1[C@H](CC(O)=O)N1C(=O)N(CCCC=2N=C3NCCCC3=CC=2)CC1 HGFOOLONGOBCMP-IBGZPJMESA-N 0.000 title claims abstract 3
108091007433 antigens Proteins 0.000 claims abstract description 103
102000036639 antigens Human genes 0.000 claims abstract description 103
239000000427 antigen Substances 0.000 claims abstract description 102
108020001507 fusion proteins Proteins 0.000 claims abstract description 67
102000037865 fusion proteins Human genes 0.000 claims abstract description 67
230000000259 anti-tumor effect Effects 0.000 claims abstract description 66
102000004127 Cytokines Human genes 0.000 claims abstract description 63
108090000695 Cytokines Proteins 0.000 claims abstract description 63
230000033115 angiogenesis Effects 0.000 claims abstract description 53
239000002955 immunomodulating agent Substances 0.000 claims abstract description 43
230000002401 inhibitory effect Effects 0.000 claims abstract description 38
239000003795 chemical substances by application Substances 0.000 claims abstract description 37
230000027455 binding Effects 0.000 claims abstract description 26
102000005962 receptors Human genes 0.000 claims abstract description 12
108020003175 receptors Proteins 0.000 claims abstract description 12
101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 claims abstract description 6
230000004663 cell proliferation Effects 0.000 claims abstract description 5
238000011282 treatment Methods 0.000 claims description 57
108090000765 processed proteins & peptides Proteins 0.000 claims description 45
239000005557 antagonist Substances 0.000 claims description 35
102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 26
206010029260 Neuroblastoma Diseases 0.000 claims description 23
102000000588 Interleukin-2 Human genes 0.000 claims description 22
108010002350 Interleukin-2 Proteins 0.000 claims description 22
201000001441 melanoma Diseases 0.000 claims description 14
108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 12
125000003275 alpha amino acid group Chemical group 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 9
108060003951 Immunoglobulin Proteins 0.000 claims description 8
102000018358 immunoglobulin Human genes 0.000 claims description 8
230000009401 metastasis Effects 0.000 claims description 8
201000003076 Angiosarcoma Diseases 0.000 claims description 7
208000001258 Hemangiosarcoma Diseases 0.000 claims description 7
239000004037 angiogenesis inhibitor Substances 0.000 claims description 7
229940121369 angiogenesis inhibitor Drugs 0.000 claims description 6
201000009030 Carcinoma Diseases 0.000 claims description 5
208000002125 Hemangioendothelioma Diseases 0.000 claims description 5
230000008512 biological response Effects 0.000 claims description 5
208000003200 Adenoma Diseases 0.000 claims description 4
206010001233 Adenoma benign Diseases 0.000 claims description 4
206010003571 Astrocytoma Diseases 0.000 claims description 4
208000000527 Germinoma Diseases 0.000 claims description 4
208000032612 Glial tumor Diseases 0.000 claims description 4
206010018338 Glioma Diseases 0.000 claims description 4
206010018852 Haematoma Diseases 0.000 claims description 4
208000002927 Hamartoma Diseases 0.000 claims description 4
101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 4
101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 4
102100021768 Phosphoserine aminotransferase Human genes 0.000 claims description 4
108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 4
206010043276 Teratoma Diseases 0.000 claims description 4
SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 claims description 4
208000037828 epithelial carcinoma Diseases 0.000 claims description 4
201000003115 germ cell cancer Diseases 0.000 claims description 4
208000005017 glioblastoma Diseases 0.000 claims description 4
208000032839 leukemia Diseases 0.000 claims description 4
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 3
102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 3
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
102100032912 CD44 antigen Human genes 0.000 claims description 3
101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 3
HBBOZFUQJDYASD-UHFFFAOYSA-N Cis-1,3-Dioxide-1,3-Dithiane Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1NC(C)=O HBBOZFUQJDYASD-UHFFFAOYSA-N 0.000 claims description 3
102000001301 EGF receptor Human genes 0.000 claims description 3
108060006698 EGF receptor Proteins 0.000 claims description 3
101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 3
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 3
101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 3
102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 3
108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 3
108010033576 Transferrin Receptors Proteins 0.000 claims description 3
208000006359 hepatoblastoma Diseases 0.000 claims description 3
206010025323 Lymphomas Diseases 0.000 claims description 2
201000000582 Retinoblastoma Diseases 0.000 claims 3
206010039491 Sarcoma Diseases 0.000 claims 3
201000008968 osteosarcoma Diseases 0.000 claims 3
201000009410 rhabdomyosarcoma Diseases 0.000 claims 3
101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
208000000172 Medulloblastoma Diseases 0.000 claims 1
102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
102000007238 Transferrin Receptors Human genes 0.000 claims 1
210000004027 cell Anatomy 0.000 description 35
238000000034 method Methods 0.000 description 32
102000004196 processed proteins & peptides Human genes 0.000 description 30
102000004169 proteins and genes Human genes 0.000 description 27
108090000623 proteins and genes Proteins 0.000 description 27
102000006495 integrins Human genes 0.000 description 25
108010044426 integrins Proteins 0.000 description 25
238000002560 therapeutic procedure Methods 0.000 description 21
229920001184 polypeptide Polymers 0.000 description 19
230000002792 vascular Effects 0.000 description 18
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
201000011510 cancer Diseases 0.000 description 17
229940123038 Integrin antagonist Drugs 0.000 description 16
241000699670 Mus sp. Species 0.000 description 16
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
230000000694 effects Effects 0.000 description 15
230000001024 immunotherapeutic effect Effects 0.000 description 15
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 14
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 14
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 14
230000002269 spontaneous effect Effects 0.000 description 14
230000001772 anti-angiogenic effect Effects 0.000 description 13
210000004204 blood vessel Anatomy 0.000 description 13
238000009169 immunotherapy Methods 0.000 description 12
210000005166 vasculature Anatomy 0.000 description 12
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 11
AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 11
239000003814 drug Substances 0.000 description 11
239000012636 effector Substances 0.000 description 11
RPLLQZBOVIVGMX-QWRGUYRKSA-N Gly-Asp-Phe Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RPLLQZBOVIVGMX-QWRGUYRKSA-N 0.000 description 10
206010027457 Metastases to liver Diseases 0.000 description 10
241001465754 Metazoa Species 0.000 description 10
241001529936 Murinae Species 0.000 description 10
230000008685 targeting Effects 0.000 description 10
102000001189 Cyclic Peptides Human genes 0.000 description 9
108010069514 Cyclic Peptides Proteins 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
239000012634 fragment Substances 0.000 description 9
238000009097 single-agent therapy Methods 0.000 description 9
230000002491 angiogenic effect Effects 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
238000002648 combination therapy Methods 0.000 description 8
230000012010 growth Effects 0.000 description 8
210000000265 leukocyte Anatomy 0.000 description 8
230000001629 suppression Effects 0.000 description 8
230000002195 synergetic effect Effects 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 7
230000014509 gene expression Effects 0.000 description 7
230000011987 methylation Effects 0.000 description 7
238000007069 methylation reaction Methods 0.000 description 7
230000009467 reduction Effects 0.000 description 7
102000019034 Chemokines Human genes 0.000 description 6
108010012236 Chemokines Proteins 0.000 description 6
201000003741 Gastrointestinal carcinoma Diseases 0.000 description 6
101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 6
208000003788 Neoplasm Micrometastasis Diseases 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
241000894007 species Species 0.000 description 6
238000010254 subcutaneous injection Methods 0.000 description 6
239000007929 subcutaneous injection Substances 0.000 description 6
238000001356 surgical procedure Methods 0.000 description 6
230000004614 tumor growth Effects 0.000 description 6
-1 KS A Proteins 0.000 description 5
238000000585 Mann–Whitney U test Methods 0.000 description 5
108091008605 VEGF receptors Proteins 0.000 description 5
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 5
238000010171 animal model Methods 0.000 description 5
230000002137 anti-vascular effect Effects 0.000 description 5
238000011398 antitumor immunotherapy Methods 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
210000002889 endothelial cell Anatomy 0.000 description 5
230000002440 hepatic effect Effects 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
206010009944 Colon cancer Diseases 0.000 description 4
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 4
JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 4
108700005091 Immunoglobulin Genes Proteins 0.000 description 4
229940083963 Peptide antagonist Drugs 0.000 description 4
238000000692 Student's t-test Methods 0.000 description 4
230000001588 bifunctional effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000008029 eradication Effects 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
238000001802 infusion Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
206010061289 metastatic neoplasm Diseases 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
230000008569 process Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
MCYJBCKCAPERSE-FXQIFTODSA-N Arg-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N MCYJBCKCAPERSE-FXQIFTODSA-N 0.000 description 3
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 3
102100032999 Integrin beta-3 Human genes 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
238000011122 anti-angiogenic therapy Methods 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000011284 combination treatment Methods 0.000 description 3
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
230000004927 fusion Effects 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
230000028993 immune response Effects 0.000 description 3
210000004969 inflammatory cell Anatomy 0.000 description 3
230000001394 metastastic effect Effects 0.000 description 3
230000001338 necrotic effect Effects 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
239000011347 resin Substances 0.000 description 3
238000011830 transgenic mouse model Methods 0.000 description 3
238000011269 treatment regimen Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
108090000144 Human Proteins Proteins 0.000 description 2
102000003839 Human Proteins Human genes 0.000 description 2
108010020950 Integrin beta3 Proteins 0.000 description 2
102000008607 Integrin beta3 Human genes 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
206010029113 Neovascularisation Diseases 0.000 description 2
101800001442 Peptide pr Proteins 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
108010067787 Proteoglycans Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
208000007660 Residual Neoplasm Diseases 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
125000002015 acyclic group Chemical group 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
230000005975 antitumor immune response Effects 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
238000001914 filtration Methods 0.000 description 2
102000006815 folate receptor Human genes 0.000 description 2
108020005243 folate receptor Proteins 0.000 description 2
230000022244 formylation Effects 0.000 description 2
238000006170 formylation reaction Methods 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
239000012071 phase Substances 0.000 description 2
229920005990 polystyrene resin Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
239000011885 synergistic combination Substances 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
239000000439 tumor marker Substances 0.000 description 2
239000013598 vector Substances 0.000 description 2
230000007998 vessel formation Effects 0.000 description 2
FFILOTSTFMXQJC-QCFYAKGBSA-N (2r,4r,5s,6s)-2-[3-[(2s,3s,4r,6s)-6-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 description 1
OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
LAWVRGYBVSVDED-JYJNAYRXSA-N (3s)-3-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-phenylethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LAWVRGYBVSVDED-JYJNAYRXSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
YYQUWEHEBOMRPH-RYLXDESZSA-N 2-[(2S,5S,8R,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid Chemical compound CC(C)[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC1=O YYQUWEHEBOMRPH-RYLXDESZSA-N 0.000 description 1
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 1
208000002699 Digestive System Neoplasms Diseases 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100025323 Integrin alpha-1 Human genes 0.000 description 1
108010041341 Integrin alpha1 Proteins 0.000 description 1
208000005016 Intestinal Neoplasms Diseases 0.000 description 1
101150088608 Kdr gene Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
238000000232 Merrifield's solid-phase procedure Methods 0.000 description 1
206010051662 Metastases to bone marrow Diseases 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
108010046722 Thrombospondin 1 Proteins 0.000 description 1
102100036034 Thrombospondin-1 Human genes 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
HBBOZFUQJDYASD-LPHOMBEVSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O HBBOZFUQJDYASD-LPHOMBEVSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001656 angiogenetic effect Effects 0.000 description 1
230000006481 angiogenic pathway Effects 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
230000002494 anti-cea effect Effects 0.000 description 1
230000006023 anti-tumor response Effects 0.000 description 1
108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
238000012832 cell culture technique Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000037516 chromosome inversion disease Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000005059 dormancy Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000004744 fabric Substances 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
238000007654 immersion Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000008975 immunomodulatory function Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
210000003757 neuroblast Anatomy 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
238000002823 phage display Methods 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
238000009163 protein therapy Methods 0.000 description 1
JFINOWIINSTUNY-UHFFFAOYSA-N pyrrolidin-3-ylmethanesulfonamide Chemical compound NS(=O)(=O)CC1CCNC1 JFINOWIINSTUNY-UHFFFAOYSA-N 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000009131 signaling function Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000013076 target substance Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Mycology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)

SK1113-2001A 1999-02-12 2000-02-11 Použitie antagonistu alfa v beta 3 na prípravu farmaceutickej kompozície na liečbu tumorových buniek a terapeutická kompozícia a súprava na liečenie tumoru alebo tumorových metastáz SK287357B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11972199P	1999-02-12	1999-02-12
PCT/US2000/003483 WO2000047228A1 (fr)	1999-02-12	2000-02-11	Methodes de traitement des tumeurs et des metastases au moyen d'une combinaison de therapies anti-angiogeniques et d'immunotherapies

Publications (2)

Publication Number	Publication Date
SK11132001A3 SK11132001A3 (sk)	2002-06-04
SK287357B6 true SK287357B6 (sk)	2010-08-09

Family

ID=22385967

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1113-2001A SK287357B6 (sk)	1999-02-12	2000-02-11	Použitie antagonistu alfa v beta 3 na prípravu farmaceutickej kompozície na liečbu tumorových buniek a terapeutická kompozícia a súprava na liečenie tumoru alebo tumorových metastáz

Country Status (22)

Country	Link
US (3)	US7115261B1 (fr)
EP (1)	EP1156823B1 (fr)
JP (2)	JP4841727B2 (fr)
KR (1)	KR100704140B1 (fr)
CN (1)	CN1192796C (fr)
AT (1)	ATE412433T1 (fr)
AU (1)	AU776790B2 (fr)
BR (1)	BR0008161A (fr)
CA (1)	CA2360106C (fr)
CZ (1)	CZ303155B6 (fr)
DE (1)	DE60040651D1 (fr)
DK (1)	DK1156823T3 (fr)
ES (1)	ES2313883T3 (fr)
HU (1)	HU229520B1 (fr)
MX (1)	MXPA01008110A (fr)
NO (2)	NO331072B1 (fr)
PL (1)	PL200919B1 (fr)
PT (1)	PT1156823E (fr)
RU (1)	RU2236251C2 (fr)
SI (1)	SI1156823T1 (fr)
SK (1)	SK287357B6 (fr)
WO (1)	WO2000047228A1 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6911204B2 (en)	2000-08-11	2005-06-28	Favrille, Inc.	Method and composition for altering a B cell mediated pathology
NZ528076A (en) *	2001-03-02	2005-09-30	Medimmune Inc	Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
TWI315982B (en)	2001-07-19	2009-10-21	Novartis Ag	Combinations comprising epothilones and pharmaceutical uses thereof
AU2002330053A1 (en) *	2001-09-20	2003-04-01	Schering Corporation	Chemokines as adjuvants of immune response
EP1454138B1 (fr)	2001-12-04	2012-01-18	Merck Patent GmbH	Immunocytokines a selectivite modulee
WO2003061566A2 (fr) *	2002-01-24	2003-07-31	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Combinaison anticancereuse et son utilisation
US8435529B2 (en)	2002-06-14	2013-05-07	Immunomedics, Inc.	Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
GB0209896D0 (en) *	2002-04-30	2002-06-05	Molmed Spa	Conjugate
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
GB0217017D0 (en) *	2002-07-23	2002-08-28	Bioacta Ltd	Peptide 2
ES2369542T3 (es)	2002-07-31	2011-12-01	Seattle Genetics, Inc.	Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
CA2497497A1 (fr) *	2002-09-04	2004-03-18	Proteinexpress Co., Ltd.	Regulateurs pour l'implantation
JP2004196770A (ja) *	2002-10-24	2004-07-15	Effector Cell Institute Inc	樹状細胞前駆体の血中レベル上昇剤
US8147832B2 (en) *	2003-08-14	2012-04-03	Merck Patent Gmbh	CD20-binding polypeptide compositions and methods
US7196061B2 (en)	2003-09-10	2007-03-27	Wyeth	Compounds that modulate neuronal growth and their uses
KR101163424B1 (ko)	2003-12-30	2012-07-13	메르크 파텐트 게엠베하	Ｉｌ－７ 융합 단백질
CN100342017C (zh) *	2004-05-10	2007-10-10	中国医学科学院肿瘤医院肿瘤研究所	基因重组趋化抗原疫苗
AU2005256113B2 (en) *	2004-07-09	2011-02-10	Chugai Seiyaku Kabushiki Kaisha	Anti-glypican 3 antibody
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
CU23297A1 (es) *	2004-11-16	2008-07-24	Ct De Inmunologa A Molecular	Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
US7662781B2 (en)	2005-01-31	2010-02-16	Eci, Inc.	Immunopotentiating agent
US20070087005A1 (en)	2005-10-14	2007-04-19	Lazar Gregory A	Anti-glypican-3 antibody
SI1964852T1 (sl) *	2005-12-20	2013-09-30	Sbi Biotech Co. Ltd.	Proti-ilt7 protitelo
US8557243B2 (en)	2008-01-03	2013-10-15	The Scripps Research Institute	EFGR antibodies comprising modular recognition domains
US8557242B2 (en)	2008-01-03	2013-10-15	The Scripps Research Institute	ERBB2 antibodies comprising modular recognition domains
EA021967B1 (ru)	2008-01-03	2015-10-30	Дзе Скриппс Рисерч Инститьют	Доставка антител посредством модульного домена распознавания
US8574577B2 (en)	2008-01-03	2013-11-05	The Scripps Research Institute	VEGF antibodies comprising modular recognition domains
US8454960B2 (en)	2008-01-03	2013-06-04	The Scripps Research Institute	Multispecific antibody targeting and multivalency through modular recognition domains
PL3118223T3 (pl) *	2008-01-04	2021-04-06	Baxalta Incorporated	Przeciwciała anty-mif do stosowania do leczenia chorób zapalnych
ES2342529B1 (es) *	2008-10-07	2011-05-11	Proyecto De Biomedicina Cima, S.L.	Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
AU2009316076B2 (en) *	2008-11-17	2015-11-19	Kobenhavns Universitet	IL-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
PL3257953T3 (pl)	2009-03-12	2019-05-31	Cancer Prevention & Cure Ltd	Sposoby identyfikacji, oceny, zapobiegania i terapii chorób płuc, ich zestawy, w tym do identyfikacji, oceny, zapobiegania i terapii chorób powiązanych z płcią
ES2363358B1 (es) *	2009-04-03	2012-06-21	FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al	Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
BRPI1006897A2 (pt) *	2009-07-06	2015-09-08	Akebia Therapeutics Inc	compostos, composições e métodos de prevenção da metástase de células cancerosas.
WO2012009705A1 (fr)	2010-07-15	2012-01-19	Zyngenia, Inc.	Complexes liant ang-2 et leurs utilisations
US11214610B2 (en)	2010-12-01	2022-01-04	H. Lundbeck A/S	High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en)	2010-12-01	2017-01-10	Alderbio Holdings, Llc	Methods of preventing inflammation and treating pain using anti-NGF compositions
US9783601B2 (en)	2010-12-01	2017-10-10	Alderbio Holdings Llc	Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en)	2010-12-01	2018-02-06	Alderbio Holdings Llc	Anti-NGF compositions and use thereof
US9078878B2 (en)	2010-12-01	2015-07-14	Alderbio Holdings Llc	Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en)	2010-12-01	2015-06-30	Alderbio Holdings Llc	Methods of preventing or treating pain using anti-NGF antibodies
RU2013139267A (ru) *	2011-02-10	2015-03-20	Рош Гликарт Аг	Улучшенная иммунотерапия
CN105440123B (zh)	2011-02-10	2020-10-09	罗切格利卡特公司	突变体白介素-2多肽
EP3825693A1 (fr) *	2011-04-29	2021-05-26	Cancer Prevention And Cure, Ltd.	Procédés d'identification et de diagnostic de maladies pulmonaires à l'aide de systèmes de classification et leurs kits
EA201892619A1 (ru)	2011-04-29	2019-04-30	Роше Гликарт Аг	Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
DK2714738T3 (en)	2011-05-24	2019-01-28	Zyngenia Inc	MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
EP2537933A1 (fr)	2011-06-24	2012-12-26	Institut National de la Santé et de la Recherche Médicale (INSERM)	Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
BR112013033944A2 (pt)	2011-07-06	2017-12-19	Morphosys Ag	combinação sinérgica
JP2014534806A (ja)	2011-08-23	2014-12-25	ロシュグリクアートアーゲー	抗ｍｃｓｐ抗体
AU2012320597C1 (en)	2011-10-07	2015-10-15	Baxalta GmbH	oxMIF as a diagnostic marker
CN102634485A (zh) *	2012-03-15	2012-08-15	上海市浦东新区公利医院	一种表达il-17的胶质瘤细胞株
US9382329B2 (en)	2012-08-14	2016-07-05	Ibc Pharmaceuticals, Inc.	Disease therapy by inducing immune response to Trop-2 expressing cells
TWI693073B (zh)	2012-12-21	2020-05-11	日商中外製藥股份有限公司	對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
CA2896053A1 (fr)	2012-12-21	2014-06-26	Ocata Therapeutics, Inc.	Procedes de production de plaquettes a partir de cellules souches pluripotentes, et compositions associees
MX2015013163A (es)	2013-03-15	2016-04-04	Zyngenia Inc	Complejos multiespecificos multivalente y monovalentes y sus usos.
JP2016518361A (ja)	2013-04-19	2016-06-23	シーチューヌファルマＣｙｔｕｎｅＰｈａｒｍａ	血管漏出症候群の発生を抑制するサイトカイン治療
AU2014309199B2 (en) *	2013-08-20	2018-04-19	Merck Sharp & Dohme Llc	Treating cancer with a combination of a PD-1 antagonist and dinaciclib
EP2915569A1 (fr)	2014-03-03	2015-09-09	Cytune Pharma	Procédé de purification de conjugués à base Il -15/IL-15Ralpha
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
KR102409014B1 (ko)	2014-05-08	2022-06-14	추가이 세이야쿠 가부시키가이샤	Gpc3 표적 치료제 요법이 유효한 환자에게 투여되는 gpc3 표적 치료제
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
WO2016086044A1 (fr) *	2014-11-24	2016-06-02	University Of Iowa Research Foundation	Méthodes de traitement du cancer
US9139653B1 (en)	2015-04-30	2015-09-22	Kymab Limited	Anti-human OX40L antibodies and methods of treatment
US11376326B2 (en)	2015-07-01	2022-07-05	Chugai Seiyaku Kabushiki Kaisha	GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
US9567399B1 (en)	2016-06-20	2017-02-14	Kymab Limited	Antibodies and immunocytokines
KR102379464B1 (ko)	2016-06-20	2022-03-29	키맵 리미티드	항-pd-l1 항체
WO2018083248A1 (fr)	2016-11-03	2018-05-11	Kymab Limited	Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
CN106906184B (zh) *	2017-02-27	2021-04-23	广东昭泰体内生物医药科技有限公司	一种促进肺癌细胞生长的方法
US20200109205A1 (en)	2017-03-31	2020-04-09	The Regents Of The University Of California	Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
CN110709936A (zh)	2017-04-04	2020-01-17	肺癌蛋白质组学有限责任公司	用于早期肺癌预后的基于血浆的蛋白质概况分析
KR102920712B1 (ko)	2017-05-24	2026-01-30	노파르티스 아게	항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
CN111562362B (zh) *	2020-04-02	2022-05-20	臻悦生物科技江苏有限公司	一组用于预测三阴乳腺癌免疫联合抗血管生成治疗效果的标志物及其应用和试剂盒
CN111440244B (zh) *	2020-04-09	2021-03-16	诺未科技（北京）有限公司	靶向vegfr2的转移性癌疫苗
CN111909962A (zh) *	2020-07-23	2020-11-10	药鼎(北京)国际细胞医学技术有限公司	一种治疗肝癌的病毒构建体及其用途和构建方法
MX2024001877A (es)	2021-08-10	2024-02-28	Kymab Ltd	Tratamiento de dermatitis atopica.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5262520A (en)	1989-12-01	1993-11-16	The Scripps Research Institute	Peptides and antibodies that inhibit integrin-ligand binding
US5314995A (en) *	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
US5650150A (en)	1990-11-09	1997-07-22	Gillies; Stephen D.	Recombinant antibody cytokine fusion proteins
ATE218889T1 (de) *	1990-11-09	2002-06-15	Stephen D Gillies	Cytokine immunokonjugate
US5753230A (en) *	1994-03-18	1998-05-19	The Scripps Research Institute	Methods and compositions useful for inhibition of angiogenesis
US5837682A (en) *	1996-03-08	1998-11-17	The Children's Medical Center Corporation	Angiostatin fragments and method of use
US5780426A (en) *	1995-06-07	1998-07-14	Ixsys, Incorporated	Fivemer cyclic peptide inhibitors of diseases involving αv β3
DE19534177A1 (de) *	1995-09-15	1997-03-20	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
PT910382E (pt) *	1996-04-26	2003-10-31	Genaera Corp	Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
CN1226254A (zh)	1996-05-31	1999-08-18	斯克里普斯研究学院	用于抑制αV、β5介导的血管发生的方法和组合物

2000
- 2000-02-11 RU RU2001124907/15A patent/RU2236251C2/ru not_active IP Right Cessation
- 2000-02-11 CA CA2360106A patent/CA2360106C/fr not_active Expired - Fee Related
- 2000-02-11 PT PT00910138T patent/PT1156823E/pt unknown
- 2000-02-11 BR BR0008161-2A patent/BR0008161A/pt not_active IP Right Cessation
- 2000-02-11 DE DE60040651T patent/DE60040651D1/de not_active Expired - Lifetime
- 2000-02-11 MX MXPA01008110A patent/MXPA01008110A/es active IP Right Grant
- 2000-02-11 US US09/502,732 patent/US7115261B1/en not_active Expired - Fee Related
- 2000-02-11 ES ES00910138T patent/ES2313883T3/es not_active Expired - Lifetime
- 2000-02-11 DK DK00910138T patent/DK1156823T3/da active
- 2000-02-11 SK SK1113-2001A patent/SK287357B6/sk not_active IP Right Cessation
- 2000-02-11 KR KR1020017010132A patent/KR100704140B1/ko not_active Expired - Fee Related
- 2000-02-11 SI SI200031012T patent/SI1156823T1/sl unknown
- 2000-02-11 EP EP00910138A patent/EP1156823B1/fr not_active Expired - Lifetime
- 2000-02-11 WO PCT/US2000/003483 patent/WO2000047228A1/fr not_active Ceased
- 2000-02-11 AU AU32280/00A patent/AU776790B2/en not_active Ceased
- 2000-02-11 CN CNB008061343A patent/CN1192796C/zh not_active Expired - Fee Related
- 2000-02-11 HU HU0200128A patent/HU229520B1/hu not_active IP Right Cessation
- 2000-02-11 AT AT00910138T patent/ATE412433T1/de active
- 2000-02-11 PL PL350329A patent/PL200919B1/pl not_active IP Right Cessation
- 2000-02-11 CZ CZ20012791A patent/CZ303155B6/cs not_active IP Right Cessation
- 2000-02-11 JP JP2000598179A patent/JP4841727B2/ja not_active Expired - Fee Related
2001
- 2001-08-10 NO NO20013906A patent/NO331072B1/no not_active IP Right Cessation
2006
- 2006-09-26 US US11/527,029 patent/US7365054B2/en not_active Expired - Fee Related
2008
- 2008-04-21 US US12/148,629 patent/US7833976B2/en not_active Expired - Fee Related
2010
- 2010-12-03 NO NO20101696A patent/NO20101696L/no not_active Application Discontinuation
2011
- 2011-05-18 JP JP2011111073A patent/JP2011207892A/ja active Pending

Also Published As

Publication number	Publication date
HU229520B1 (en)	2014-01-28
EP1156823B1 (fr)	2008-10-29
SI1156823T1 (sl)	2009-02-28
NO20101696L (no)	2001-10-09
JP4841727B2 (ja)	2011-12-21
EP1156823A1 (fr)	2001-11-28
NO331072B1 (no)	2011-09-26
BR0008161A (pt)	2002-05-28
NO20013906D0 (no)	2001-08-10
US7365054B2 (en)	2008-04-29
US7833976B2 (en)	2010-11-16
PT1156823E (pt)	2009-01-08
JP2002536419A (ja)	2002-10-29
US7115261B1 (en)	2006-10-03
SK11132001A3 (sk)	2002-06-04
CZ20012791A3 (cs)	2002-05-15
AU776790B2 (en)	2004-09-23
ES2313883T3 (es)	2009-03-16
MXPA01008110A (es)	2002-10-23
US20070036751A1 (en)	2007-02-15
ATE412433T1 (de)	2008-11-15
US20090060864A1 (en)	2009-03-05
CN1192796C (zh)	2005-03-16
CA2360106C (fr)	2012-10-30
RU2236251C2 (ru)	2004-09-20
PL350329A1 (en)	2002-12-02
DE60040651D1 (de)	2008-12-11
EP1156823A4 (fr)	2003-02-19
DK1156823T3 (da)	2009-01-19
WO2000047228A1 (fr)	2000-08-17
PL200919B1 (pl)	2009-02-27
KR20010102043A (ko)	2001-11-15
CZ303155B6 (cs)	2012-05-09
NO20013906L (no)	2001-10-09
CA2360106A1 (fr)	2000-08-17
CN1346279A (zh)	2002-04-24
JP2011207892A (ja)	2011-10-20
AU3228000A (en)	2000-08-29
KR100704140B1 (ko)	2007-04-09
HUP0200128A2 (en)	2002-05-29

Legal Events

Date	Code	Title	Description
2014-11-04	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20140211

Publication	Publication Date	Title
EP1156823B1 (fr)	2008-10-29	Methodes de traitement des tumeurs et des metastases au moyen d'une combinaison de therapies anti-angiogeniques et d'immunotherapies
Lode et al.	1998	Immunocytokines: a promising approach to cancer immunotherapy
US20050074426A1 (en)	2005-04-07	Fusions of cytokines and tumor targeting proteins
IL183710A (en)	2012-01-31	Conjugated product
JPH08505764A (ja)	1996-06-25	腫瘍血管内皮細胞に特異的に結合するモノクローナル抗体とその利用方法
AU4413501A (en)	2001-08-27	Modified cytokines for use in cancer therapy
US20050063948A1 (en)	2005-03-24	Methods for targeting interleukin-12 to malignant endothelium
CA2504963C (fr)	2013-09-03	Conjugues de tnf et un ligand du recepteur cd13 utilises en combinaison avec des interferons gamma pour le traitement du cancer
WO2004078137A2 (fr)	2004-09-16	Agents antitumoraux comprenant une partie de ciblage et une partie de declenchement de reponse immunitaire
ZA200106455B (en)	2002-11-06	Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies.
HK1106781B (en)	2012-12-21	Conjugation product